Takeda Pharmaceuticals North America
Who We Are Working At Takeda Takeda Commitment News/Events Contact Us
actos actoplus met duetact
amitiza rozerem pipeline
actos
Takeda Pharmaceuticals North America, Inc. currently markets the oral diabetes treatment ACTOS® (pioglitazone HCl) in the United States. Since its U.S. launch in 1999, more than 30 million prescriptions for ACTOS have been written.

ACTOS is an insulin sensitizer for people with type 2 diabetes. ACTOS is a member of the class of oral diabetes agents called thiazolidinediones (THIGH-ah-ZO-li-deen-DYE-owns, TZDs). Scientists at TPNA’s parent company, Takeda Pharmaceutical Company Limited, were leaders in the discovery of the TZD molecule and have been instrumental in advancing the class. The U.S. Food and Drug Administration approved ACTOS in July 1999. In September 2002, ACTOS became the number one prescribed TZD in the United States. In April 2003, TPNA announced the initiation of two significant trials to investigate the effect of ACTOS on reducing the risk for cardiovascular disease in patients with type 2 diabetes.

As an adjunct to diet and exercise, ACTOS may be used as monotherapy to lower blood glucose, and in combination with sulfonylureas, metformin, or insulin when diet and exercise plus the single agent do not result in adequate glycemic control. ACTOS should not be used in type 1 diabetes or for the treatment of diabetic ketoacidosis. Management of type 2 diabetes should also include nutritional counseling, weight reduction as needed, and exercise.

To learn more about type 2 diabetes and ACTOS, visit www.actos.com or view the ACTOS Complete Prescribing Information.

Clinical trials are research studies conducted on new drugs or treatments in the pharmaceutical industry to test if they are safe and effective for patients. A clinical trial seeks to answer questions and find solutions to provide patients the safest, best treatment for a disease or illness.

Clinical trials depend on people who volunteer to try a new drug or treatment. In some cases, a drug has not yet been approved by the Food and Drug Administration (FDA) to be sold in the United States. Or, the drug has been approved, but it is being tested for a different treatment or additional information.

There are four different "phases" of clinical development:

  • Phase 1: This type of trial involves a small group of people (20-80), and it is the first time a drug is tested in people. Researchers study whether the drug is safe and identify side effects and safe dosage amounts. This phase usually includes healthy volunteer subjects.
  • Phase 2: This type of trial involves more people (100-300) than a Phase I trial, and it is typically is the first time the drug is tested in a patient population for which the drug is being developed. The primary purpose for this type of trial is to assess the drug’s effectiveness in the patient population for which it is intended. Researchers continue to study the drug’s safety
  • Phase 3: During this phase of clinical development, trials usually involve a large group of people (1,000-3,000). Researchers evaluate how the patients are reacting to the drug – evaluating whether the drug is helping treat the patient as it should, monitoring additional side effects, comparing it to commonly used treatments and continuing to study ways for the drug to be used safely
  • Phase 4: Commonly called post-marketing studies, this type of trial continues to focus on the drug’s safety, effectiveness and the best way the drug should be used.

For more information please view:

Glossary of Clinical Trials
Clinical Trials Frequently Asked Questions

who we are  -  working at takeda  -  takeda commitment  -  news / events  -  contact us
privacy policy  -  terms of use
© Copyright 2008 Takeda Pharmaceuticals North America, Inc.